ReviewClinical & translational immunology2020
Interleukin (IL)-33: an orchestrator of immunity from host defence to tissue homeostasis.
Review in Clinical & translational immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Circulating interleukin-33 levels in obesity and type 2 diabetes: a systematic review and meta-analysis.American journal of physiology. Endocrinology and metabolism · 2024Pooled it
- Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations.BMJ open respiratory research · 2026Article
- Lim Homeobox 8 Is Essential for Beta Adrenergic Stimulation of Thermogenesis in Human Adipocytes.Cells · 2026Article
- Cross-kingdom dialogs in the gut: Integrating bacterial pathogens, helminths, and microbiota interactions for immune homeostasis.PLoS pathogens · 2025Review
- Effect of Nematodes-Bacteria Complex Metabolites on Cancer and Tumor Progression.Biomolecules · 2025Review
- Innate Immunity and Asthma Exacerbations: Insights From Human Models.Immunological reviews · 2025Review
- Interleukin-33 and Obesity-Related Inflammation and Cancer.Encyclopedia · 2024Article
- Decoding the IL-33/ST2 Axis: Its Impact on the Immune Landscape of Breast Cancer.International journal of molecular sciences · 2023Review
- Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction.Scientific reports · 2023Article
- Cell-scaffold interactions in tissue engineering for oral and craniofacial reconstruction.Bioactive materials · 2023Article
- Adiponectin and Interleukin-33: Possible Early Markers of Metabolic Syndrome.Journal of clinical medicine · 2022Article
- Review
- Regulatory T cells-centered regulatory networks of skeletal muscle inflammation and regeneration.Cell & bioscience · 2022Review
- Hepatic pannexin-1 mediates ST2Clinical and translational medicine · 2022Article
- Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer.Frontiers in immunology · 2022Review
- Interleukin-33: Metabolic checkpoints, metabolic processes, and epigenetic regulation in immune cells.Frontiers in immunology · 2022Review
- IL-33 Deficiency Attenuates Lung Inflammation by Inducing Th17 Response and Impacting the Th17/Treg Balance in LPS-Induced ARDS Mice via Dendritic Cells.Journal of immunology research · 2022Article
- Phosphonate-Modified Cellulose Nanocrystals Potentiate the Th1 Polarising Capacity of Monocyte-Derived Dendritic Cells via GABA-B Receptor.International journal of nanomedicine · 2022Article
- Review
- Nuclear IL-33 as a growth and survival agent within basal cells.The Journal of clinical investigation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin (IL)-33, a member of the IL-1 superfamily, functions as an alarm signal, which is released upon cell injury or tissue damage to alert the immune system. It has emerged as a chief orchestrator in immunity and has a broad pleiotropic action that influences differentiation, maintenance and function of various immune cell types via the ST2 receptor. Although it has been strongly associated with immunopathology, critically, IL-33 is involved in host defence, tissue repair and homeostasis. In this review, we provide an overview of the signalling pathway of IL-33 and highlight its regulatory functions in immune cells. Furthermore, we attempt a broader discussion of the emerging functions of IL-33 in host defence, tissue repair, metabolism, inflammatory disease and cancer, suggesting potential avenues to manoeuvre IL-33/ST2 signalling as treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.